Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-12-30
2002-04-09
Rotman, Alan L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S433000, C514S434000, C514S543000, C546S114000, C546S261000, C549S015000, C549S021000, C560S135000
Reexamination Certificate
active
06369071
ABSTRACT:
CROSS-REFERENCE
This application is a 371 of PCT/iL 98/00144 filed Mar. 26, 1998 which claims the benefit of Israel priority application 120,531 filed Mar. 26, 1997.
FIELD OF THE INVENTION
There are provided novel organic compounds and pharmaceutical compositions comprising same. The compounds are in vivo nitric oxide donors and they contain at least one sulfhydryl group, either in the reduced —SH form or in the oxidized —S—S disulfide form. Preferably the compounds containing the —S—S groups are five- or six membered heterocyclic compounds, where such a group is part of the heterocyclic nucleus, to which there may be attached directly or via a hydrocarbyl chain, which may be optionally substituted, one or more —ONO
2
groups.
The —S—S group may be a bridging member between to cyclic or two hereocyclic moieties each of which bears at least one —ONO
2
group.
Another suitable group of compounds comprises a 5- or 6-membered aromatic ring substituted with an —SH group and a —ONO
2
bearing group and there are also provided compounds having a 5-membered ring system containing a nitrogen and a non-adjacent S atom, substituted by at least one group bearing an —ONO
2
substituent and which may have also an —SH group as substituent.
All the above compounds are such that they will undergo in vivo metabolic cleavage to provide free —SH groups.
The novel compounds are effective substitutes for existing tolerance inducing organic or inorganic nitric oxide donors.
BACKGROUND OF THE INVENTION
For over a century, the nitric oxide (NO) donor nitroglycerin (GTN) has been the mainstay in the treatment of angina and related heart diseases. However, the existing mechanisms proposing the mediation of GTN action by free NO, intracellular or extracellular S-nitrosothiol formation and subsequent activation of guanylyl cyclase (GC), as well as those describing GTN tolerance, have become increasingly controversial. The phenomenon of tolerance to GTN, however, is of special clinical importance. In fact, early tolerance to the anti-anginal effects of the drug is the major drawback of nitrate therapy, especially during acute myocardial infarction. This is particularly important since alternative non-tolerance inducing agents have not yet been developed to successfully replace therapy with GTN.
Based on accumulating evidence from our laboratory, we hypothesize that GTN may directly interact with SH-group/s located on its target enzyme (GC) resulting in its S-nitrosylation and activation. However, subsequent auto-oxidation (disulfide-formation) of these SH-groups render the enzyme inert towards further reaction with GTN, resulting in tolerance development.
Additionally, evidence has recently been provided to support an involvement of the superoxide anion in the mechanism/s underlying GTN tolerance and cross-tolerance. According to these reports, increased production of superoxide anion was found to accompany tolerance development to GTN in vascular tissue. Treatment with superoxide dismutase (SOD), significantly enhanced relaxation of control and tolerant vascular tissue to GTN and other exogenous and endogenous vasodilators.
While the precise mechanism for the vasorelaxant effect of GTN is unknown, a consensus exists regarding the primary involvement of cGMP in mediating the nitrate-induced relaxation. However, the roles of sulfhydryl groups [reduced glutathione (GSH) and cysteine (Cys)] and of various enzymes in the bioconversion of GTN and subsequent activation of guanylyl cyclase (GC) leading to relaxation have become increasingly controversial. Cysteine was found to be the specific sulfhydryl required for activation of soluble coronary arterial GC and to be the only one of several sulfhydryls to react non-enzymatically with GTN at physiologic pH resulting in formation of S-nitrosocysteine. Since S-nitrosothiols were shown to be potent activators of GC, S-nitrosocysteine/thiols were proposed as the intracellular mediators of organic nitrate-induced vasorelaxation. Additionally, N-acetylcysteine (NAC, an immediate donor of Cys thereby increasing GSH) was reported to potentiate GTN activity in vitro and in vivo. The enhanced reaction of thiols with GTN in plasma and blood versus buffer suggested that activation of GC by GTN may be mediated via extracellular formation of S-nitrosothiol/s. In either case (intra or extracellular S-nitrosothiol formation), this association between sulfhydryls and GTN activity has long been recognized as evidence for the “thiol depletion hypothesis”. However, recent studies from our laboratory and those of Boesgard et al., revealed a dissociation between tissue thiol content (measured as Cys and GSH) and nitrate tolerance in vivo.
In vitro inhibitory studies provide indirect support for the involvement of enzymes in GTN bioactivation [glutathione S-transferase (GST) and cytochrome P-450 (P-450)]. However, in view of several other reports suggesting the lack of any significant role of GST and P-450, in GTN bioactivation, the reduced bioactivation of GTN is unlikely to be the main factor underlying nitrate tolerance in vivo. In fact, reduced cGMP production was also shown to follow exposure of vascular preparation to direct NO-donors, for which no definitive metabolic pathway has been reported.
Furthermore, recent work from our laboratory presented in vivo evidence excluding the involvement of any particular metabolic pathway since reduced cGMP was also shown to follow treatment with S-alkylating agents in the absence of GTN.
Each sulfhydryl may be present in a free form (SH), separately protected form (acetyl, carbamyl or other), or as an atom in a heterocyclic compound. In cases where the a compound contains two sulfhydryl groups, these can exist in the reduced (SH) or the oxidized (disulfide) form. However, each one of the compounds can also be regarded as a parent pro-drug which is assumed to undergo metabolic reduction or cleavage to provide the free SH groups in vivo.
Heart disease is the leading cause of death in Western society and is rapidly approaching this leading position worldwide. Ischemic heart disease is the most common heart disease. For over a century, nitroglycerin and other organic nitrates have been used for the treatment of various types of myocardial ischemia, including acute myocardial infarction (AMI), and as adjuncts in the treatment of other heart diseases (congestive heart failure and resistant hypertension). Chronic prophylaxis and acute treatment are necessary to prevent complications of ischemic heart disease with potential fatal outcomes (~25% death for AMI). Tolerance to the anti-ischemic effect of these drugs is, by far, the most serious drawback of therapy with currently available organic nitrates. The compounds proposed in this application constitute a novel approach to overcome tolerance.
Because of their SH-content (radical scavenging and anti-oxidant properties), these compounds may also be applied for other pathologies. Thus, considering their promising chemical and pharmacological characteristics and the ever increasing demand for better therapy for heart diseases significant potential exists for compounds of this type to become, the next generation of vasodilators. This is especially true concerning the considerable amount of recent evidence indicating the involvement of nitric oxide, reactive oxygen species and thiols in a variety of conditions, the pathogenesis of which as well as the treatment for, have not been fully resolved. These include (but not limited to): atherosclerosis, pulmonary and systemic hypertension, asthma and other related respiratory diseases, trauma, shock, neurotoxicity, neurodegenerative and neurologic disorders, including those involving learning, memory, olfaction and nociception, Huntington, Alzheimer and Parkinson's diseases, multiple sclerosis and convulsive (seizure) disorders, AIDS-related disorders (i.e., dementia), disorders of gastric acid and other secretory and peristaltic functions of the alimentary system, drug and disease-induced neuropathy and nephropathy, pathological an
Eitan Pearl Latzer & Cohen-Zedek
Rotman Alan L.
Yissum Research Development Company of The Hebrew University of
LandOfFree
Nitric oxide donors and pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitric oxide donors and pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitric oxide donors and pharmaceutical compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2877845